CME Outfitters Medical Education

In this CME Outfitters recorded webcast, expert faculty will use real-world cases and perspectives from across the gMG care team to strengthen candidate recognition, evidence-based treatment selection, longitudinal monitoring, and shared decision-making. Education will clarify team roles and support individualized care, addressing symptom fluctuation, safety, administration preferences, treatment burden, and outcomes most meaningful to patients, including minimal symptom expression and preserved daily function.

Learn More Here

In this CME Outfitters Snack, expert faculty will assist learners to explore the role of FGF21 across metabolic and fibrotic pathways, interpret emerging clinical evidence for FGF21 analogues in clinically significant MASH, and examine the scientific rationale for targeting the FGF21 pathway in patients with compensated cirrhosis due to MASH.

Learn More Here

As the fourth and final segment, this conversation brings the series full circle. After framing obesity’s heterogeneity, exploring amylin biology, and considering phenotype-guided care, it turns to the closing question: as these therapies arrive, how do we evaluate them — and whom might they help? A forward-looking, evidence-grounded finish for clinicians preparing for what comes next. All data discussed are investigational and presented as such.

Learn More Here

In this conversation, Andres Acosta, MD, PhD, joins series chair Robert F. Kushner, MD, to explore obesity phenotypes as a framework for individualizing care. Dr. Acosta examines how differences in appetite, satiety, energy expenditure, and eating behavior may help explain the wide variation in treatment response — and offers a candid appraisal of how far the science has come and how far it still has to go, since validated predictors of drug response are not yet established.

As the third of four conversations, this segment turns the series’ theme of heterogeneity into a practical lens. After framing why multiple pathways are needed and exploring the biology of amylin, it asks how clinicians might one day match patient to pathway.

Learn More Here

In the third activity of this CMEO podcast series, expert faculty will assist learners to recognize common and clinically significant extraintestinal manifestations associated with IBD, incorporate practical screening approaches into routine clinical workflows, and implement multidisciplinary care strategies for patients with systemic disease involvement.

Learn More Here

In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.

In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promise of phenotype-guided care, and the emerging trial data that follow across three more expert conversations. Short, practical, and forward-looking — an essential primer for any clinician preparing for the next era of obesity care.

Learn More Here

In this second CMEO Snack of the Riding the Waves of Obesity Science series, amylin researcher Matthew R. Hayes, PhD joins moderator Robert F. Kushner, MD for a focused, practical conversation that turns amylin from a half‑remembered footnote into working clinical knowledge; what amylin actually does, how its calcitonin‑receptor/receptor activity-modifying protein (RAMP) biology shapes today’s drug classes, and why its signal complements rather than duplicates glucagon-like peptide-1 (GLP‑1). Designed for physicians, nurse practitioners, physician associates, and pharmacists across obesity medicine, endocrinology, primary care, and cardiometabolic practice, this activity will help you read the emerging science with a sharper eye and be ready for the amylin‑based therapies that may be on the horizon.

Learn More Here

Idiopathic hypersomnia (IH) is a life-disrupting condition characterized by excessive daytime sleepiness (EDS) that makes waking up a daily struggle, limits productivity, and erodes overall quality of life. For many patients with IH, the journey to diagnosis is long and frustrating atop the disease burden itself. Overlapping symptoms with conditions such as depression, anxiety, and cardiovascular disease often obscure the true cause, while distinguishing IH itself from narcoleptic sleep disorders can be equally complex. As a rare condition, IH can leave patients feeling isolated and misunderstood while enduring an unpredictable constellation of symptoms. By sharpening diagnostic precision and fostering collaboration across multidisciplinary teams, clinicians can unlock new opportunities in the therapeutic landscape to deliver personalized, patient-centered care that addresses the unique challenges of living with IH.

This fast-paced and highly interactive recorded CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply guideline-recommended diagnostic criteria and comprehensive assessments into practice when there is clinical suspicion of IH to improve early and accurate diagnosis.

Learn More Here

The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes and apply emerging evidence to routine practice. With antibody-drug conjugates (ADCs) transforming the treatment landscape, today’s oncology and pathology teams need practical guidance that connects diagnostic precision with therapeutic decision-making to improve patient outcomes.

In the first activity of this EfficientCME webcast series, two leading breast oncologists and a partnering pathologist examine the evolving understanding of HER2 biology and explain why new testing and interpretation methods for HER2-low and ultralow expression in mBC are emerging. Through expert discussion, they explore key evidence driving this shift and what it means for clinical practice moving forward.

Learn More Here

Fibrosis remains one of the greatest unmet needs in inflammatory bowel disease (IBD), contributing to irreversible structural bowel damage, complications, and long-term morbidity despite advances in anti-inflammatory therapies. Many gastroenterologists and multidisciplinary gastrointestinal (GI) care teams lack confidence in recognizing patients at risk for fibrotic progression and inconsistently apply objective monitoring and management strategies until complications have already developed. In addition, evolving insights into the biologic mechanisms driving chronic tissue remodeling and emerging therapeutic approaches targeting these pathways have not yet been fully integrated into routine clinical practice. This podcast, designed for gastroenterologists, GI fellows, physician associates, nurse practitioners, nurses, and pharmacists will strengthen understanding of fibrosis pathogenesis, improve risk stratification and monitoring practices, and support earlier, outcomes-focused intervention in patients with IBD.

In the second activity of this CMEO podcast series, expert faculty will assist learners to examine the biologic pathways involved in IBD-related fibrosis, recognize clinical characteristics and disease patterns associated with fibrotic progression, and implement objective monitoring and management approaches to evaluate ongoing structural bowel damage.

Learn More Here